期刊文献+

脂肪酸受体GPR84及其调节剂的研究进展

Advanced in free fatty acid receptor GPR84 and its modulators
原文传递
导出
摘要 G蛋白偶联受体84(GPR84)属于脂肪酸受体,能被中链脂肪酸(C9-C14)激活。人体内GPR84主要表达在骨髓,其次表达在外周白细胞和肺,在生理状态下GPR84表达量较低,炎症刺激(如脂多糖)可诱导GPR84在单核/巨噬细胞中高表达,可知GPR84与炎症有很大关系。许多疾病的发生发展伴随着炎症反应,而GPR84小分子调节剂能调节炎症反应,从而干预相关疾病的进程。本文主要就GPR84与各类疾病的关系,以及GPR84小分子调节剂的研究展开综述。 GPR84 belongs to free fatty acid receptors (FFAR) and it is mainly activated by MCFA (C9-14). GPR84 is highly expressed in human bone marrow, and to a lesser extent, in the peripheral leukocytes and lungs. In physiological conditions, the expression of GPR84 is low, but it can increase remarkably in mono- cytes/macrophages upon activation by lipopolysaccharide. Several recent studies also showed that GPR84 plays a significant role in inflammation, and GPR84 modulators therefore have potential use in regulating in- flammation. In this review, we summariTe tho re^o~nt ~rl ~^-UOOn ~_a : J 1 ,
出处 《生命的化学》 CAS CSCD 2016年第4期548-555,共8页 Chemistry of Life
关键词 G蛋白偶联受体 中链脂肪酸 G蛋白偶联受体84 炎症 调节剂 GPCR medium chain fatty acid (MCFA) GPR84 inflammation modulator
  • 相关文献

参考文献1

二级参考文献20

  • 1S. C. Ng,Y. T. Lam,K. K. F. Tsoi,F. K. L. Chan,J. J. Y. Sung,J. C. Y. Wu.Systematic review: the efficacy of herbal therapy in inflammatory bowel disease[J].Aliment Pharmacol Ther.2013(8)
  • 2Shomron Ben-Horin,Uri Kopylov,Yehuda Chowers.Optimizing anti-TNF treatments in inflammatory bowel disease[J].Autoimmunity Reviews.2013
  • 3T. Lobatón,S. Vermeire,G. Assche,P. Rutgeerts.Review article: anti‐adhesion therapies for inflammatory bowel disease[J]. Aliment Pharmacol Ther . 2014 (6)
  • 4Andrea Warman,Jan Willem A. Straathof,Luc J.J. Derijks.Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study[J]. European Journal of Gastroenterology & Hepatology . 2015 (3)
  • 5Y. Mazor,R. Almog,U. Kopylov,D. Ben Hur,A. Blatt,A. Dahan,M. Waterman,S. Ben‐Horin,Y. Chowers.Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease[J]. Aliment Pharmacol Ther . 2014 (6)
  • 6Mamoru Watanabe,Naoki Yoshimura,Satoshi Motoya,Keiichi Tominaga,Ryuichi Iwakiri,Kenji Watanabe,Toshifumi Hibi.370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study[J]. Gastroenterology . 2014 (5)
  • 7Charlotte P. Peters,Emma J. Eshuis,Florien M. Toxopeüs,Merel E. Hellemons,Jeroen M. Jansen,Geert R.A.M. D’Haens,Paul Fockens,Pieter C.F. Stokkers,Hans A.R.E. Tuynman,Adriaan A. van Bodegraven,Cyriel Y. Ponsioen.Adalimumab for Crohn’s disease: Long-term sustained benefit in a population-based cohort of 438 patients[J]. Journal of Crohn’s and Colitis . 2014
  • 8Lawrence B. Cohen,Radu M. Nanau,Faustine Delzor,Manuela G. Neuman.Biologic therapies in inflammatory bowel disease[J]. Translational Research . 2014
  • 9Alessandro Antonelli,Silvia Martina Ferrari,Dilia Giuggioli,Ele Ferrannini,Clodoveo Ferri,Poupak Fallahi.Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases[J]. Autoimmunity Reviews . 2013
  • 10K.R. Herrlinger,M. Diculescu,K. Fellermann,H. Hartmann,S. Howaldt,R. Nikolov,A. Petrov,W. Reindl,J.M. Otte,S. Stoynov,U. Strauch,A. Sturm,R. Voiosu,A. Ammendola,B. Dietrich,B. Hentsch,E.F. Stange.Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study[J]. Journal of Crohn’s and Colitis . 2013 (8)

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部